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Abstract
Pediatric patients suffering from ependymoma are usually treated with cranial or
craniospinal three‐dimensional (3D) conformal radiotherapy (3DCRT). Intensity‐
modulated techniques spare dose to the surrounding tissue, but the risk for second
malignancies may be increased due to the increase in low‐dose volume. The aim of
this study is to investigate if the ﬂattening ﬁlter free (FFF) mode allows reducing
the risk for second malignancies compared to the mode with ﬂattening ﬁlter (FF) for
intensity‐modulated techniques and to 3DCRT. A reduction of the risk would be
advantageous for treating pediatric ependymoma. 3DCRT was compared to inten-
sity‐modulated radiation therapy (IMRT) and volumetric‐modulated arc therapy
(VMAT) with and without ﬂattening ﬁlter. Dose–volume histograms (DVHs) were
compared to evaluate the plan quality and used to calculate the excess absolute risk
(EAR) to develop second cancer in the brain. Dose veriﬁcation was performed with
a two‐dimensional (2D) ionization chamber array and the out‐of‐ﬁeld dose was mea-
sured with an ionization chamber to determine the EAR in peripheral organs. Deliv-
ery times were measured. Both VMAT and IMRT achieved similar plan quality in
terms of dose sparing in the OAR and higher PTV coverage as compared to 3DCRT.
Peripheral dose in low‐dose region, which is proportional to the EAR in organs
located in this region, for example, gonads, bladder, or bowel, could be signiﬁcantly
reduced using FFF. The lowest peripheral EAR and lowest delivery times were
hereby achieved with VMATFFF. The EAR calculated based on DVH in the brain
could not be reduced using FFF mode. VMATFFF improved the target coverage and
homogeneity and kept the dose in the OAR similar compared to 3DCRT. In addition,
delivery times were signiﬁcantly reduced using VMATFFF. Therefore, for radiother-
apy of ependymoma patients, VMATFFF may be considered advantageous for the
combination of Elekta Synergy linac and Oncentra External Beam planning system
used in this study.
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1 | INTRODUCTION
The standard therapy for childhood ependymoma is surgery followed
by adjuvant radiation.1,2 Historically, cranial or craniospinal irradia-
tion was the standard treatment after surgery3 in order to assure
that the volume adjacent to the target receives adequate dose and
consequently assure local control. However, recent publications have
shown that conformal, intensity‐modulated (IMRT) and proton‐beam
radiotherapy can achieve similar local control rates to those
published in historical publications without an increased risk of mar-
ginal failure.4–7
An advantage of IMRT over three‐dimensional (3D) conformal
standard technique is to spare dose in surrounding normal tissues.
However, a concern about the IMRT treatment is that the volume
that receives a low dose can be signiﬁcantly higher compared to
those volumes for conventional technique. This might increase the
risk for second malignancies, which is a very important issue with
regard to the life expectancy of these pediatric patients.8
A recent development in the linear accelerator technology is the
irradiation without a ﬂattening ﬁlter in the beam path to increase
dose rate and reduce beam‐on time.9 A reduction of the treatment
time would represent an additional advantage, especially in the treat-
ment of pediatric patients. The ﬂattening ﬁlter produces scatter radi-
ation; therefore, its removal has the positive effect of reducing the
out‐of‐ﬁeld dose,10 which may lead to reduced second cancer risk as
it has been shown for the treatment of breast cancer in a previous
study.11 To our knowledge, no reports about second cancer risk
have been published for ependymoma. The excess absolute risk
(EAR) of developing a second cancer after exposure to radiation
(EAR) can be estimated from dose–volume histograms (DVHs) based
on biological models which are ﬁtted to data of atomic bomb sur-
vivors and Hodgkin patients treated with radiation therapy.12,13
The purpose of our study was therefore to investigate whether
the ﬂattening ﬁlter free mode (FFF) is advantageous with respect to
the second cancer risk, plan quality, and delivery time after radiation
therapy of ependymoma as compared with the ﬂat beam mode (FF).
2 | MATERIALS AND METHODS
2.A | Patients and treatment planning
Computed tomography (CT) data of 11 pediatric patients with ependy-
moma were selected from our treatment database for a retrospective
planning study. The age of the patients ranged from 22 months to
15 yr with a mean of 6.5 yr and a median of 4.6 yr. All patients were
completely resected and without metastases. The irradiation approach
was used in this planning study in the same way as in the HIT Interim
Register for children under 4 yrs14 (dose per fraction 1.8 Gy, total
dose 50.4 Gy). HIT stands for brain tumors in children. The precursor
was the HIT 2000 study, a multicenter therapy optimization study,
which provided optimal and risk‐adapted therapy nationwide in
Germany and Austria for patients up to the age of 21 with an intracra-
nial localized medulloblastoma, PNET, or ependymoma. Following the
completion of the HIT 2000 study, the HIT Interims Register study
was launched to bridge the period until the relaunch of the study with
the same standard of quality.
The patients were in supine position and an individual thermo-
plastic facial mask was created. The planning CT was then performed
in 4 mm layer thickness from occiput to the third cervical vertebral
body in a multislice CT Siemens® Somatom Sensation Open. The
planning CT was imported into the planning system and it was fused
with the magnetic resonance tomography (T1‐weighted, contrast‐
enhanced MRI) before and after surgery (MRI equipment: 1.5T Sie-
mens® Magnetom Avanto and Siemens® Magnetom Symphony). The
planning target volume (PTV) was the expanded tumor region, which
means the former tumor region (GTV = gross tumor region), includ-
ing two centimeter of automatically generated safety margin taking
into account anatomical limits or rearrangement of brain tissue into
the resection area after surgery. Dose threshold was based on the
tolerance doses for organs at risk (OAR) of the protocol of Radiation
Therapy Oncology Group Trial 0225.15 Dose to the normal tissue
(patient outline excluding the PTV) should be kept as low as possible
to minimize the risk of second cancer induction.8
Treatment planning was performed with Oncentra External
Beam®4.5.2 with collapsed cone dose calculation algorithm for a
Synergy linear accelerator with Agility™ head (Elekta AB, Stockholm,
Sweden). Five treatment plans with 6 MV photons were created for
each patient: step and shoot IMRT and VMAT plans both with and
without ﬂattening ﬁlter (IMRTFF, IMRTFFF, VMATFF, and VMATFFF)
and a conventional ﬁve‐ﬁeld 3D‐plan (3DCRT). IMRT plans consisted
of nine coplanar beams (20°, 60°, 95°, 140°, 180°, 220°, 265°, 300°,
and 340°). The VMAT plans were performed with a single full rota-
tion with gantry spacing between two control points of 4°. Dose–
volume objectives (DVO) used for VMAT and IMRT optimization are
listed in Table 1. DVOs to the OAR were set to values which could
be achieved in 3DCRT. Identical DVO were used for optimization of
all plans. The dose calculation was performed with a grid size of
3 mm and the dose was normalized to the average dose in the PTV.
All plans were accepted for treatment by a radiation oncologist.
2.B | Dosimetry and peripheral low‐dose
measurement
Dose veriﬁcation of all IMRT and VMAT plans was performed with
the MatriXX Evolution™ 2D ionization chamber array (IBA Dosime-
try, Schwarzenbruck, Germany) positioned between a 10 cm
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(bottom) and a 9.7 cm (top) stack of RVW slabs (PTW, Freiburg, Ger-
many). AAPM TG119 recommendations were used for the dose veri-
ﬁcation acceptance.16,17 Gamma indices18 were calculated with a
dose tolerance of 3% of the maximum dose and 3 mm distance to
agreement and the gamma criterion was considered fulﬁlled if γ < 1
in at least 95% of the pixels.
In the low‐dose region, the EAR presents a linear dose–re-
sponse.19,20 Since planning CT data do not include images at larger
distances for reasons of radiation protection, no calculations of the
EAR based on DVH are possible, for example, bladder, bowel, and
gonads. Various studies have previously shown large uncertainties
for dose calculations in the out‐of‐ﬁeld area and therefore recom-
mended to perform point dose measurements instead of calculations
in this area.9,21,22 Therefore, we performed dose measurements in
the same coronal plane in the low‐dose region at a distance of
31 cm cranial of the isocenter using a 0.3 ccm ionization chamber
(PTW) simultaneously with 2D veriﬁcation (Fig. 1). The target is
symmetric in cranial‐caudal direction; therefore, the measurements
can also be associated with the dose in the caudal region. The
results were compared for the ﬁve irradiation techniques for the
whole series. The complete setup is shown in Fig. 1.
Simultaneously, total delivery times were measured from ﬁrst
beam on to last beam off.
2.C | Excess absolute risk calculation and organ
equivalent dose
The excess absolute risk (EAR) to develop a solid cancer describes
the absolute difference in cancer rates of persons exposed to a dose
d and those not exposed to a dose beyond the natural dose exposi-
tion per 10,000 person‐year and is described as23
EARðD; e; aÞ ¼ EAR0 REDðDÞlðe; aÞ
where RED (risk equivalent dose) is the dose–response relationship
for radiation‐induced cancer in units of dose and EAR0 the initial
slope (slope of the dose–response curve at low dose). The function μ
depends on the attained age a and age at exposure e:
lðe; aÞ ¼ expðceða-30Þ þ ca lnða=70ÞÞ
For this study, the EAR values are calculated for gender‐averaged
persons at an age at exposure of 10 yr and an attained age of 70 yr
and reported per 10,000 person‐years. EAR0, γe, and γa values have
TA B L E 1 DVO used for optimization and tolerance dose for each structure.
Structure Type Objective Dose (Gy) Weight Distance (cm) Tolerance dose15 (Gy)
PTV Target Minimum 50.4 10000 47.9
PTV Target Maximum 50.5 8000 52.9
PTV Target Uniform dose 50.4 1000 50.4
Inner ears OAR Maximum average 33.0 200 50.0
Chiasma OAR Maximum 25.0 800 50.0
Pituitary OAR Maximum 30.0 800 30.0
Lens OAR Maximum 5.0 300 10.0
Optic nerve OAR Maximum 15.0 200 54.0
Bulbus oculi OAR D50% 5.0 200 35.0
Normal tissue OAR Dose falloff 50.4–33.0 20000 0.8 –
Normal tissue OAR Dose falloff 50.4–25.2 2000 1.6 –
F I G . 1 . Measurement setup.
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been derived by Preston et al.20 from the data of the Japanese
atomic bomb survivors (EAR0 = 0.7 per 10,000 person‐years per Gy
for the brain, γe = −0.024, and γa = 2.38). Large errors are involved
in the determination of the parameters EAR0 and μ; therefore, abso-
lute risk results have to be viewed with care.
It is known, that for doses below 2 Gy, the dose–response is lin-
ear.8 For higher doses, the concept of an organ equivalent dose
(OED), which is proportional to EAR, has been deﬁned by Schneider
et al.12,13:
OED ¼
1
VT
X
i
VðDiÞREDðDiÞ
Therefore, risk ratios for different treatment plans are equivalent
to OED ratios which can be determined with the RED function and
DVH.
There are different models for the RED calculation, based on dif-
ferent assumptions on the behavior of cells after dose exposition.23
The linear model assumes a linear response over the whole dose
range:
REDðDÞ ¼ D
The mechanistic model accounts for cell killing and fractionation
effects23,24:
REDðDÞ ¼
ea
0D
a0R
1 2Rþ R2ea
0D  ð1 RÞ2
 
e
a0Rð ÞD
1R
where /0¼/ þb D
DT
dT
For this model, there are two limit cases: when the parameter R
is 0 if no and 1 if full repopulation/repair occurs. Therefore, the limit
R = 0 leads to the linear‐exponential model:
REDðDÞ ¼ Dexpða0DÞ
Moreover, the limit R = 1 is the case of full repopulation/repair,
known as plateau model:
REDðDÞ ¼
1 expða0DÞ
a0
The parameters α and β are those from the linear quadratic
model of cell killing. The parameter R describes the repopulation and
repair ability between dose fractions. The parameters α′ = 0.018 and
R = 0.93 for the brain have been derived from a combined ﬁt to the
data of atomic bomb survivors and Hodgkin patients treated with
doses up to 40 Gy assuming that α/β = 3 Gy.23 α′ is 0.009 in case of
no fractionation (linear‐exponential limit) and 0.021 in case of full tis-
sue recovery (plateau limit).
As mentioned before, the parameters used in the calculation
of absolute EAR involve large errors. In order to keep the uncer-
tainties at minimum, we opted to use the OED values for evalua-
tion of the risk of second cancer when comparing different
radiation techniques. EAR absolute values were also calculated for
the sake of completeness.
Previous studies have demonstrated that for inhomogeneous
dose distributions above 4 Gy, the linear‐exponential, the plateau,
and the full mechanistic model represent a better description of the
dose–response function compared to the linear model.12,23 There-
fore, this model was not included in our results.
2.D | Evaluation
Plan quality was assessed by the analysis of the DVH for the PTV
and OARs. Target coverage was represented by the volume of the
PTV covered by 95% of the prescription dose (V95%). The homo-
geneity index was deﬁned as HI = (D2% − D98%)/D50%, the conformity
index25 as CI = V95%
2
/(TV·PIV). Here, TV means the volume of the
PTV, PIV the total volume covered by 95% of the prescription dose.
Relevant clinical parameters were evaluated for the OARs.
Differences between the irradiation modes were assumed to be
clinically relevant when larger than the standard deviation within
one group, which corresponds to an effect size of 1. For testing the
two‐sided Wilcoxon signed‐rank test for matched pairs was used
since this test does not require a normal parent distribution. Power
analysis for the Wilcoxon test, however, requires assumptions for
the parent distribution. Therefore, a priori power analysis according
to Cohen26 was performed for various assumptions for the parent
distribution to determine the required total sample size N for a sta-
tistical signiﬁcance level of 0.05, a power of 0.8, and an effect size
of 1 using the software G*Power version 3.1.9.2.27,28 The calculated
sample size was N = 11 for a normal parent distribution, N = 7 for a
Laplace distribution, and N = 10 for a logistic distribution. A sample
size of N = 11 was therefore chosen for this study.
The two‐sided Wilcoxon signed‐rank test implemented in IBM
SPSS® Statistics 23.0 (IBM Corporation) was used to detect relevant
differences with a signiﬁcance level of 0.05. Due to multiple pairwise
comparisons,29 Holm–Bonferroni30 step‐down method for multiple
testing was applied to control the maximum experimentwise error
rate (MEER).31
3 | RESULTS
A comparison of dose distributions and DVH for all techniques and
modes is shown in Fig. 2 for one typical case. Isodoses are shown
for the range of 10–110% of 50.4 Gy. In the sagittal slice, the low‐
dose region is represented for the range of 1–4% for better compar-
ison of the dose distribution in low‐dose region.
Plan quality was evaluated by means of the DVH and dose distri-
butions. Details of relevant DVH parameters are given in Table 2
averaged over all patients. Threshold doses listed in Table 1 were
met in all 55 plans. FFF modes led to signiﬁcantly higher CI and HI
of the target compared to 3DCRT. IMRTFFF led to a signiﬁcantly
superior target CI, HI, and V95%. No signiﬁcant differences were
found between VMATFFF and VMATFF in the PTV. All dose–volume
parameters evaluated for the OARs were similar without signiﬁcant
differences between IMRT and VMAT (comparing FF and FFF
modes). The comparison of IMRTFFF/VMATFFF with the standard plan
3DCRT led to a signiﬁcant lower dose for the inner ears, right lens,
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and bulbus oculi when using FFF. On the contrary, in the structure
brain‐PTV and normal tissue, comparison of FFF modes with 3DCRT
led to a signiﬁcantly lower dose when 3DCRT was used as treatment
technique. When comparing FFF with FF in IMRT and VMAT, the
evaluated parameter in low‐dose area V4Gy in the normal tissue was
signiﬁcantly lower when using FFF.
Since no plan exceeded the threshold values, all plans achieved
acceptable plan quality in terms of dose sparing in the OARs.
3.A | Dosimetry and delivery
Gamma evaluation of the veriﬁcation of dose calculation is shown in
Table 3. All 44 IMRT and VMAT plans passed the evaluation with
passing rates >95% as recommended by the AAPM TG119.16,17 On
average, IMRTFFF achieved a higher gamma passing rate than the
other techniques, but no signiﬁcant differences were found.
Total delivery times are also listed in Table 3. Both VMAT modes
reduced the delivery time signiﬁcantly (P = 0.003) by 50% compared
to 3DCRT. Both IMRT modes doubled signiﬁcantly the delivery time
compared to 3DCRT (P = 0.003).
Peripheral dose was measured with an ionization chamber in the
measurement setup of Fig. 1; the measured doses are listed in
Table 3. It was observed that FFF reduced the peripheral dose sig-
niﬁcantly compared with FF techniques for IMRT and VMAT tech-
niques as well as for 3DCRT. The signiﬁcantly lowest peripheral
dose was found for VMATFFF.
3.B | Excess absolute risk of developing secondary
cancer and organ equivalent dose
Table 4 shows the calculated OED values for the linear‐exponential,
plateau, and full mechanistic dose–response model. 3DCRT was the
technique with the lowest OED values. When comparing 3DCRT
with VMATFF/FFF, the advantage of 3DCRT was signiﬁcant in all
three models, whereas the 3DCRT advantage over IMRTFF/FFF was
found not signiﬁcant. No signiﬁcant differences were found between
IMRTFF/FFF, whereas VMATFFF values were signiﬁcantly lower than
VMATFF. IMRTFF could achieve signiﬁcant lower OED values when
compared with VMATFF. The same behavior was observed for
IMRTFFF/VMATFFF.
For completeness, EAR values are listed in Table 5. The values
are proportional to OED; no statistical analysis of the data has been
performed because of the large uncertainties of the factors EAR0
and μ used in the calculation.
Volume
[%]
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 Dose [Gy]
3DCRT
IMRTFF
IMRTFFF
VMATFF
VMATFFF
bulbus oculi R
bulbus oculi L
lens R
lens L
chiasma
optic nerve R
optic nerve L
pituitary
PTV
inner ear L
inner ear R
brain-PTV
normal tissue
3DCRT
3DCRT
IMRTFF
IMRTFFF
IMRTFFFIMRTFF
VMATFFF
VMATFFF
VMATFF
VMATFF
50.40 Gy = 100%
50.40 Gy = 100%
125.0
115.0
110.0
105.0
100.0
95.0
90.0
80.0
70.0
50.0
10.0
110.0
105.0
100.0
95.0
90.0
80.0
70.0
50.0
4.0
2.0
1.0
F I G . 2 . Comparison of dose distributions and DVH for a typical case in a transversal and sagittal slice.
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4 | DISCUSSION
The main objective of this study is to investigate the potential of the
FFF mode of a linear accelerator to reduce the radiation‐induced
second cancer risk, the treatment time, and to improve the treat-
ment plan quality in pediatric ependymoma.
The major concern of using inverse treatment planning for the
treatment of ependymoma is that the high‐dose falloff at the mar-
gin of the PTV might lead to a decrease of the local tumor control.
However, recent publications for ependymoma showed that the
local control and overall survival achieved with IMRT are not infe-
rior to those associated with conventional therapy.4,32,33 We per-
formed a DVH comparison of ﬁve different techniques: 3DCRT,
IMRTFF/FFF, and VMATFF/FFF to determine if target coverage or
OAR dose sparing is being compromised using inverse techniques.
The results indicate that, for all IMRT and VMAT techniques, the
homogeneity and conformity indexes are similar or even improved
signiﬁcantly (FFF mode) as compared to 3DCRT. Regarding the
OARs, since all threshold values were fulﬁlled, we assume that
inverse techniques do not affect the plan quality. These results
TA B L E 2 Treatment plan comparison.
3DCRT IMRTFF IMRTFFF VMATFF VMATFFF
PTV V95% (%) 97.2 ± 0.7 96.3 ± 0.8 97.7 ± 0.7
s 99.1 ± 0.6 99.0 ± 0.7
HI 0.09 ± 0.01 0.09 ± 0.01 0.08 ± 0.01s 0.06 ± 0.01 0.06 ± 0.01
CI 0.84 ± 0.06 0.90 ± 0.04 0.89 ± 0.04s 0.86 ± 0.04 0.87 ± 0.04
Inner ear L D50% 35.7 ± 7.2 30.9 ± 4.3 30.5 ± 4.1 31.4 ± 4.6 31.0 ± 4.6
Inner ear R D50% 33.8 ± 8.0 28.7 ± 6.9 28.7 ± 6.3 29.5 ± 5.4 29.6 ± 6.1
Chiasma D2% 23.6 ± 8.7 24.0 ± 4.6 24.2 ± 3.9 23.9 ± 4.7 24.2 ± 4.3
Pituitary D2% 23.9 ± 8.9 24.1 ± 6.2 24.7 ± 5.9 23.9 ± 4.9 23.8 ± 5.1
Lens L Dmax 4.0 ± 2.4 3.8 ± 2.2 3.7 ± 2.1 3.6 ± 1.6 3.6 ± 1.9
Lens R Dmax 4.7 ± 2.7 3.6 ± 1.9 3.6 ± 2.0 3.6 ± 1.6 3.4 ± 1.8
Optic nerve L Dmax 13.9 ± 3.7 16.5 ± 3.1 16.6 ± 3.3 15.4 ± 0.8 14.9 ± 2.0
Optic nerve R Dmax 14.6 ± 3.1 16.7 ± 2.8 16.7 ± 3.7 15.3 ± 1.3 15.7 ± 0.9
Bulbus oculi L Dmean 3.9 ± 2.2 4.2 ± 2.3 4.2 ± 2.3 4.2 ± 1.9 4.2 ± 2.2
Bulbus oculi R Dmean 4.7 ± 2.7 4.1 ± 2.3 4.1 ± ± 2.3 4.1 ± 1.9 3.9 ± 2.0
Brain‐PTV D50% 4.5 ± 2.3 6.2 ± 4.1 6.0 ± 4.1 6.7 ± 3.8 6.4 ± 4.0
Dmean 11.1 ± 1.0 11.6 ± 1.8 11.4 ± 1.8 12.3 ± 1.6 12.0 ± 1.8
s
Normal tissue D50% 3.4 ± 1.8 4.0 ± 2.1 3.9 ± 2.0 4.8 ± 2.1 4.4 ± 2.9
s
V4 Gy (%) 46.9 ± 6.4 48.5 ± 6.7 48.0 ± 6.8
s 51.0 ± 6.3 49.9 ± 6.5s
Values are averaged over all patients; standard deviation is given for all values. All values are given in Gy except V95% and V4Gy in percentage of the
structure volume. L and R indicate left and right. Values highlighted in bold are statistically signiﬁcant when comparing IMRTFFF with 3DCRT and
VMATFFF with 3DCRT. s indicates that the value is statistically signiﬁcant when comparing both IMRT modes and both VMAT modes. For the PTV, con-
formity index (CI) and homogeneity index (HI) were evaluated: CI = (TV95%)
2
/(TV·V95%), where TV95% is the target volume covered by the 95% isodose,
TV is the target volume, and V95% is the volume of the reference isodose; HI = (D2% − D98%)/D50%.
TA B L E 3 Total delivery time, peripheral dose (DIC) and gamma passing rate of the dose veriﬁcation.
3DCRT IMRTFF IMRTFFF VMATFF VMATFFF
Time 142 ± 9 293 ± 43 288 ± 32 72 ± 3 72 ± 7
DIC 32.78 ± 4.18 40.67 ± 6.41 28.12
s ± 5.35 34.54 ± 3.03 24.67s ± 3.44
Gamma passing rate – 97.84 ± 1.47 99.02 ± 0.99 97.05 ± 1.24 97.38 ± 1.01
Total delivery time measured in seconds. DIC in mGy measured with an ionization chamber at 31 cm of isocenter for 28 fractions. Values highlighted in
bold are statistically signiﬁcant when comparing IMRTFFF with 3DCRT and VMATFFF with 3DCRT. S indicates that the value is statistically signiﬁcant
when comparing both IMRT modes and both VMAT modes.
TA B L E 4 OED in the brain and standard deviation.
Plan OEDlin-exp OEDplateau OEDmech
3DCRT 8.60 ± 0.85 8.41 ± 0.83 7.58 ± 0.78
IMRTFF 9.09* ± 1.51 8.89* ± 1.48 8.08* ± 1.39
IMRTFFF 8.99* ± 1.56 8.79* ± 1.53 7.98* ± 1.43
VMATFF 9.67 ± 1.40 9.46 ± 1.37 8.58 ± 1.29
VMATFFF 9.41 ± 1.52 9.20 ± 1.50 8.34 ± 1.40
Values in italic are signiﬁcant when comparing both VMATFF/FFF with
3DCRT, bold indicates that the value is statistically signiﬁcant when com-
paring VMATFFF to VMATFF, *indicates statistically signiﬁcant when com-
paring IMRTFF with VMATFF and IMRTFFF with VMATFFF.
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indicate that the local tumor control would not be compromised
using inverse techniques.
The total delivery time becomes an important issue when treat-
ing pediatric patients. Our study showed that VMAT represents an
advantage for treating those patients. In both irradiation modes, FF
as well as FFF, VMAT could reduce the delivery time to the half
compared to 3DCRT. An additional advantage of FFF over FF could
not be observed. This can be explained by the fact that the maxi-
mum dose rate was not exploited in VMATFFF, since the minimum
time of 1 minute required for one rotation was already nearly
achieved in FF mode, as it has already been mentioned in a previous
study for hypopharynx carcinoma.34
Pediatric patients are particularly vulnerable to radiation expo-
sure. The peripheral dose in pediatric radiation has been previously
investigated by Mansur et al.35 Their investigation showed that the
peripheral dose at large distances using 3DCRT was lower than using
IMRT. Since planning CT do not include the peripheral region, no
calculations of the second cancer risk based on DVH are possible.
Various studies have previously shown large uncertainties for dose
calculations in the out‐of‐ﬁeld area and therefore recommended to
perform point dose measurements instead of calculations in this
area.9,21,22,36 Therefore, peripheral dose measurements were per-
formed and compared at a distance of 31 cm to the isocenter. These
measurements can be associated with the location of peripheral
organs such as gonads, bladder, bowel, or stomach, depending on
the size of the patient. The results of our study are comparable with
the study mentioned above. No signiﬁcant differences could be
observed in peripheral dose between VMAT/IMRTFF and 3DCRT.
However, removing the ﬂattening ﬁlter allows a signiﬁcant reduction
of the peripheral doses compared to 3DCRT. The peripheral dose
reduction was found to be 15% in case of IMRTFFF and 25% in case
of VMATFFF. Due to the linearity of the dose–response for doses up
to 2 Gy, the EAR in organs situated at large distances of the PTV is
proportional to DIC. Therefore, the EAR to organs in the region of
the peripheral dose measurement could be reduced by 15% for
IMRTFFF and 25% for VMATFFF. To calculate the OED and EAR in
the tissue near the PTV, three different dose–response models have
been calculated based on DVH data of the structure brain‐PTV. The
dose calculation performed with Oncentra External Beam®4.5.2 was
veriﬁed with a 2D array to assure that the DVHs can be used for
calculating the EAR. Although the study demonstrated that the use
of ﬂattening ﬁlter free beams reduces the peripheral dose at large
distances, this could not be translated into a general reduction of
the second cancer risk for structures near to the tumor. The FFF
mode allowed a signiﬁcant reduction as compared to the ﬂat beam
mode for VMAT. For IMRT, no signiﬁcant differences were found
between both irradiation modes. The lowest EAR of all plans was,
however, achieved with 3DCRT.
The results of our study did not show any advantage of using
IMRTFF/VMATFF over the standard 3DCRT technique. IMRTFFF
allowed reducing the peripheral dose compared to 3DCRT, but the
irradiation time was signiﬁcantly higher compared to other tech-
niques. For this reason, it would not be recommended for treating
pediatric patients. For VMATFFF, a signiﬁcant reduction of the
peripheral dose and irradiation time was observed.
The Holm–Bonferroni step‐down method for multiple testing
was applied to the comparison of HI, CI, time, EARmech, and DIC for
3DCRT vs VFFF to control MEER. No hypothesis had to be rejected;
therefore, all signiﬁcant results remained signiﬁcant after the test.
5 | CONCLUSION
The results of this study show that VMATFFF is a technique to con-
sider for treating childhood ependymoma. Compared to the standard
technique used for ependymoma, VMATFFF achieved signiﬁcantly
higher PTV coverage and allowed reducing treatment time signiﬁ-
cantly. The risk of radiation‐induced secondary cancer, which is a
major concern in radiation therapy of pediatric patients, was signiﬁ-
cantly reduced for organs located at large distance from the target,
for example, bladder, gonads, or bowel. No advantage could be
observed with respect to the secondary cancer risk in the brain.
ACKNOWLEDGMENTS
This study was funded by the Bavarian State Ministry of the Envi-
ronment and Consumer Protection. The publication was supported
by the German Research Foundation (DFG) within the funding pro-
gram Open Access Publishing.
CONFLICT OF INTEREST
The authors declare that there is no conﬂict of interest regarding
the publication of this article.
REFERENCES
1. Rousseau P, Habrand JL, Sarrazin D, et al. Treatment of intracranial
ependymomas of children: review of a 15‐year experience. Int J
Radiat Oncol Biol Phys. 1994;28:381–386.
2. Mork SJ, Loken AC. Ependymoma: a follow‐up study of 101 cases.
Cancer. 1977;40:907–915.
3. Salazar OM, Rubin P, Bassano D, Marcial VA. Improved survival of
patients with intracranial ependymomas by irradiation: doseselection
and ﬁeld extension. Cancer. 1975;35:1563–1573.
4. Schroeder TM, Chintagumpala M, Okcu MF, et al. Intensity‐modu-
lated radiation therapy in childhood ependymoma. Int J Radiat Oncol
Biol Phys. 2008;71:987–993.
TA B L E 5 Excess absolute risk (EAR) for brain.
Plan EARlin-exp EARplateau EARmech
3DCRT 9.73 9.51 8.58
IMRTFF 10.28 10.06 9.15
IMRTFFF 10.17 9.94 9.03
VMATFF 10.94 10.70 9.71
VMATFFF 10.65 10.41 9.43
ALVAREZ MORET ET AL. |
5. Weber DC, Zilli T, Do HP, Nouet P, Gumy Pause F, Pica A. Intensity
modulated radiation therapy or stereotactic fractionated radiother-
apy for infratentorial ependymoma in children: a multicentric study. J
Neurooncol. 2011;102:295–300.
6. Sato M, Gunther JR, Mahajan A, et al. Progression‐free survival of
children with localized ependymoma treated with intensity‐modu-
lated radiation therapy or proton‐beam radiation therapy. Cancer.
2017;123:2570–2578.
7. MacDonald SM, Safai S, Troﬁmov A, et al. Proton radiotherapy for
childhood ependymoma: initial clinical outcomes and dose compar-
isons. Int J Radiat Oncol Biol Phys. 2008;71:979–986.
8. Hall EJ, Wuu C-S. Radiation‐induced second cancers: the impact of
3D‐CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83–88.
9. Georg D, Knoos T, McClean B. Current status and future perspective
of ﬂattening ﬁlter free photon beams. Med Phys. 2011;38:1280–
1293.
10. Kragl G, Baier F, Lutz S, et al. Flattening ﬁlter free beams in SBRT
and IMRT: dosimetric assessment of peripheral doses. Z Med Phys.
2011;21:91–101.
11. Dobler B, Maier J, Knott B, Maerz M, Loeschel R, Koelbl O. Second
cancer risk after simultaneous integrated boost radiation therapy of
right sided breast cancer with and without ﬂattening ﬁlter. Strahlen-
ther Onkol. 2016;192:687–695.
12. Schneider U, Walsh L. Cancer risk estimates from the combined
Japanese A‐bomb and Hodgkin cohorts for doses relevant to radio-
therapy. Radiat Environ Biophys. 2008;47:253–263.
13. Schneider U, Zwahlen D, Ross D, Kaser-Hotz B. Estimation of radia-
tion‐induced cancer from three‐dimensional dose distributions: con-
cept of organ equivalent dose. Int J Radiat Oncol Biol Phys.
2005;61:1510–1515.
14. Informationsportal zu Krebs- und Bluterkrankungen bei Kindern und
Jugendlichen. https://www.kinderkrebsinfo.de/health_professiona
ls/clinical_trials/closed_trials/hit_2000/index_eng.html.
15. Lee N, Harris J, Garden AS, et al. Intensity‐modulated radiation ther-
apy with or without chemotherapy for nasopharyngeal carcinoma:
radiation therapy oncology group phase II trial 0225. J Clin Oncol.
2009;27:3684–3690.
16. Ezzell GA, Burmeister JW, Dogan N, et al. IMRT commissioning: mul-
tiple institution planning and dosimetry comparisons, a report from
AAPM Task Group 119. Med Phys. 2009;36:5359–5373.
17. Ezzell GA, Galvin JM, Low D, et al. Guidance document on delivery,
treatment planning, and clinical implementation of IMRT: report of
the IMRT subcommittee of the AAPM Radiation Therapy Commit-
tee. Med Phys. 2003;30:2089–2115.
18. Low DA, Harms WB, Mutic S, Purdy JA. A technique for the
quantitative evaluation of dose distributions. Med Phys.
1998;25:656–661.
19. Preston DL, Pierce DA, Shimizu Y, et al. Effect of recent changes in
atomic bomb survivor dosimetry on cancer mortality risk estimates.
Radiat Res. 2004;162:377–389.
20. Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic
bomb survivors: 1958–1998. Radiat Res. 2007;168:1–64.
21. Covington EL, Ritter TA, Moran JM, Owrangi AM, Prisciandaro JI.
Technical report: evaluation of peripheral dose for ﬂattening ﬁlter
free photon beams. Med Phys. 2016;43:4789.
22. Howell RM, Scarboro SB, Taddei PJ, Krishnan S, Kry SF, Newhauser
WD. Methodology for determining doses to in‐ﬁeld, out‐of‐ﬁeld and
partially in‐ﬁeld organs for late effects studies in photon radiother-
apy. Phys Med Biol. 2010;55:7009–7023.
23. Schneider U, Sumila M, Robotka J. Site‐speciﬁc dose‐response rela-
tionships for cancer induction from the combined Japanese A‐bomb
and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol
Med Model. 2011;8:27.
24. Schneider U. Mechanistic model of radiation‐induced cancer after
fractionated radiotherapy using the linear‐quadratic formula. Med
Phys. 2009;36:1138–1143.
25. Paddick I. A simple scoring ratio to index the conformity of radiosur-
gical treatment plans. Technical note. J Neurosurg. 2000;93:219–222.
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed.
Hillsdale, NJ: L. Erlbaum Associates; 1988.
27. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses
using G*Power 3.1: tests for correlation and regression analyses.
Behav Res Methods. 2009;41:1149–1160.
28. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a ﬂexible sta-
tistical power analysis program for the social, behavioral, and
biomedical sciences. Behav Res Methods. 2007;39:175–191.
29. Bender R, Lange S. Adjusting for multiple testing – when and how? J
Clin Epidemiol. 2001;54:343–349.
30. Sture Holm. A simple sequentially rejective multiple test procedure.
Scand J Stat. 1979;6:65–70.
31. Bauer P. Multiple testing in clinical trials. Stat Med. 1991;10:871–
889; discussion 889-90.
32. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Confor-
mal radiotherapy after surgery for paediatric ependymoma: a
prospective study. Lancet Oncol. 2009;10:258–266.
33. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from
a phase II trial of conformal radiation therapy and evaluation of radi-
ation‐related CNS effects for pediatric patients with localized
ependymoma. J Clin Oncol. 2004;22:3156–3162.
34. Dobler B, Obermeier T, Hautmann MG, Khemissi A, Koelbl O. Simul-
taneous integrated boost therapy of carcinoma of the hypopharynx/
larynx with and without ﬂattening ﬁlter – a treatment planning and
dosimetry study. Radiat Oncol. 2017;12:114.
35. Mansur DB, Klein EE, Maserang BP. Measured peripheral dose in
pediatric radiation therapy: a comparison of intensity‐modulated and
conformal techniques. Radiother Oncol. 2007;82:179–184.
36. Dobler B, Khemissi A, Obermeier T, Hautmann MG, Katsilieri Z,
Kolbl O. Re‐irradiating spinal column metastases using IMRT and
VMAT with and without ﬂattening ﬁlter – a treatment planning
study. Radiat Oncol. 2016;11:33.
8 | ALVAREZ MORET ET AL.
